| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPLX4 |
| Uniprot No | Q7Z7G2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-157aa |
| 氨基酸序列 | MAFLMKSMIS NQVKNLGFGG GSEENKEEGG ASDPAAAQGM TREEYEEYQK QMIEEKMERD AAFTQKKAER ACLRVHLREK YRLPKSEMDE NQIQMAGDDV DLPEDLRKMV DEDQEEEEDK DSILGQIQNL QNMDLDTIKE KAQATFTEIK QTAEQKC |
| 预测分子量 | 18,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant CPLX4 regulates synaptic vesicle exocytosis in neuronal models"**
- Authors: Smith J, et al.
- Summary: 研究利用重组CPLX4蛋白探究其在突触囊泡分泌中的作用，发现其通过稳定SNARE复合物增强神经递质释放效率。
2. **"Structural and functional analysis of CPLX4 in neurodevelopmental disorders"**
- Authors: Lee H, et al.
- Summary: 通过重组CPLX4蛋白解析其晶体结构，揭示其与自闭症相关突变的关联，并验证其调控突触可塑性的分子机制。
3. **"CPLX4 recombinant protein rescues cognitive deficits in a mouse Alzheimer's model"**
- Authors: Chen R, et al.
- Summary: 在小鼠模型中证明重组CPLX4蛋白可改善β淀粉样蛋白沉积导致的认知障碍，提示其潜在治疗神经退行性疾病的应用价值。
4. **"High-yield expression and purification of human CPLX4 for biochemical assays"**
- Authors: Gonzalez M, et al.
- Summary: 开发高效重组CPLX4蛋白表达纯化系统，优化其体外活性检测方法，为后续功能研究提供技术基础。
(注：上述文献为模拟示例，实际引用需查询PubMed、Web of Science等数据库获取真实论文。)
**Background of CPLX4 Recombinant Protein**
CPLX4 (Complexin-4) is a member of the complexin family of small, soluble synaptic proteins that play critical roles in regulating neurotransmitter release. Complexins are essential for synchronizing synaptic vesicle fusion with calcium signaling during exocytosis, acting as both facilitators and inhibitors of SNARE complex assembly. CPLX4. specifically, is expressed in select neuronal populations and has been implicated in fine-tuning the precision of synaptic transmission, particularly in circuits requiring high temporal fidelity, such as auditory or visual pathways.
Recombinant CPLX4 protein is engineered using molecular cloning techniques, where the *CPLX4* gene is inserted into expression vectors (e.g., bacterial, insect, or mammalian systems) to produce purified, functional protein. This allows researchers to study its biochemical interactions, structural properties, and regulatory mechanisms in vitro. Unlike endogenous complexins, recombinant CPLX4 can be tagged (e.g., His-tag, GFP) for easier detection or purification, enabling advanced applications like crystallography, binding assays, or functional studies in reconstituted membrane systems.
Research on CPLX4 has shed light on its dual role in neurosecretion: stabilizing the primed SNARE complex to prevent spontaneous fusion while simultaneously enhancing calcium-triggered release. Dysregulation of complexins, including CPLX4. has been linked to neurological disorders such as epilepsy, schizophrenia, and autism spectrum disorders. Recombinant CPLX4 is thus a vital tool for dissecting synaptic dysfunction mechanisms and screening potential therapeutics targeting synaptic transmission. Its study also contributes to broader neuroscience goals, including understanding neural circuit plasticity and information coding in the brain.
(Word count: 249)
×
